Clinical Trials · NCT05348122
A Study of TG103 Injection in Type 2 Diabetes Subjects
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Enrollment
- 240
- Start date
- Jun 2022
- Locations
- 1 site, China
- Primary endpoint
- Changes in glycosylated hemoglobin (HbA1c) from baseline to week 17